edralbrutinib

Edralbrutinib (SHR1459, TG-1701) is a potent, highly selective, orally available, and covalently-bound small molecule inhibitor of Bruton's tyrosine kinase (BTK). Developed by Jiangsu Hengrui Medicine, it is designed to inhibit the phosphorylation of BTK and down-regulate the B-cell receptor (BCR) signal transduction pathway, which selectively suppresses the proliferation and migration of malignant B cells. Edralbrutinib is being investigated for the treatment of various B-cell malignancies, including follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia, as well as autoimmune conditions such as primary membranous nephropathy and neuromyelitis optica spectrum disorders (NMOSD). TG Therapeutics holds worldwide development rights for the compound, excluding Japan.

Other names

atuzabrutinib